Epidermolysis Bullosa Clinical Trial
Official title:
A Double-blind, Randomized, Placebo-controlled, Interventional, Multicenter, Phase III Clinical Trial to Investigate the Safety and Efficacy of ABCB5-positive Mesenchymal Stromal Cells (ABCB5+ MSCs) on Epidermolysis Bullosa (EB)
The aim of this clinical trial is to investigate the safety and efficacy of allo-APZ2-OTS administered intravenously to subjects with recessive dystrophic epidermolysis bullosa (RDEB) compared to placebo.
Status | Recruiting |
Enrollment | 74 |
Est. completion date | December 1, 2025 |
Est. primary completion date | December 1, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 6 Months and older |
Eligibility | Inclusion Criteria: 1. Male or female subjects from 6 months of age with a diagnosis of RDEB confirmed by genetic testing or by a skin biopsy with immunofluorescence mapping 2. Subject is eligible to participate in this clinical trial based on general health condition; 3. Subject with a target wound meeting the following criteria: 5-50 cm2, = 21 days and < 9 months, no signs of acute infection; 4. Patient/legal representative understands the nature of the procedure and provide written informed consent/assent prior to any clinical trial procedure; 5. Women of childbearing potential must have a negative urine pregnancy test at Visit 1. Women of childbearing potential, male participants, and their partner must be willing to use highly effective contraceptive methods during the course of the entire clinical trial. Exclusion Criteria: 1. Any current tumor diseases, including squamous cell carcinoma and basal cell carcinoma; 2. Any known allergies to components of the IP or premedication; 3. Patient/legal representative anticipated to be unwilling or unable to comply with the requirements of the protocol; 4. Pregnant or lactating women; 5. Current or previous (within 30 days of screening) treatment with another IP, or participation and/or under follow-up in another interventional clinical trial; 6. Previous participation in this clinical trial (except for screening failures); 7. Clinically significant or unstable concurrent disease or other clinical contraindications like an uncontrolled or poorly controlled mental health condition of the subject and/or his/her legal representative that could impact on patient's safety or interfere with study compliance such as inability to attend scheduled study visits; Confidential 8. Employees of the sponsor, or employees or relatives of the investigator. |
Country | Name | City | State |
---|---|---|---|
United States | Masonic Cancer Center and Medical Center Minneapolis | Minneapolis | Minnesota |
Lead Sponsor | Collaborator |
---|---|
RHEACELL GmbH & Co. KG |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Proportion of subjects with complete target wound closure | Proportion of subjects with complete healing of target wound, determined by the investigator, as compared to baseline | 12 months | |
Secondary | Time to complete target wound closure from baseline | 12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00380640 -
The Efficacy of Trimethoprim in Wound Healing of Patients With Epidermolysis Bullosa
|
Phase 2 | |
Completed |
NCT00004761 -
Establishment of the National Epidermolysis Bullosa Registry
|
N/A | |
Completed |
NCT01263379 -
Gene Transfer for Recessive Dystrophic Epidermolysis Bullosa
|
Phase 1/Phase 2 | |
Completed |
NCT01716169 -
Treatment of Chronic and Non-Chronic Wounds in Patients With Recessive Dystrophic Epidermolysis Bullosa Using Helicoll Collagen Dressings Versus Standard of Care
|
N/A | |
Withdrawn |
NCT01454687 -
Grafting of Epidermolysis Bullosa Wounds Using Cultured Revertant Autologous Keratinocytes
|
N/A | |
Completed |
NCT00014729 -
Phase I Study of Isotretinoin in Patients With Recessive Dystrophic Epidermolysis Bullosa
|
Phase 1 | |
Recruiting |
NCT03269474 -
Computational Drug Repurposing for All EBS Cases
|
||
Completed |
NCT03068780 -
Phase III Efficacy and Safety Study of Oleogel-S10 in Epidermolysis Bullosa
|
Phase 3 | |
Terminated |
NCT02090283 -
Open-Label Extension Study to Evaluate the Safety of SD-101 Cream in Participants With Epidermolysis Bullosa
|
Phase 2 | |
Completed |
NCT02582775 -
MT2015-20: Biochemical Correction of Severe EB by Allo HSCT and Serial Donor MSCs
|
Phase 2 | |
Recruiting |
NCT04213703 -
A Pilot Study to Explore the Role of Gut Flora in Epidermolysis Bullosa
|
||
Completed |
NCT02384460 -
ESSENCE Study: Efficacy and Safety of SD-101 Cream in Participants With Epidermolysis Bullosa
|
Phase 3 | |
Terminated |
NCT02670330 -
Open Label Extension Study to Evaluate the Long-term Safety of Zorblisa (SD-101-6.0) in Patients With Epidermolysis Bullosa
|
Phase 3 | |
Terminated |
NCT01619670 -
A Observational Study to Evaluate Apligraf(R) in Nonhealing Wounds of Subjects With Epidermolysis Bullosa
|
Phase 4 | |
Recruiting |
NCT01340235 -
Treatment of Dowling Maera Type of Epidermolysis Bullosa Simplex by Oral Erythromycin
|
Phase 3 | |
Completed |
NCT02014376 -
Study of Effectiveness and Safety of SD-101 in Participants With Epidermolysis Bullosa
|
Phase 2 | |
Completed |
NCT04217538 -
Observational Study of a Cohort of Patients With Hereditary Epidermolysis Bullosa
|
||
Completed |
NCT03942250 -
Uses of Irradiated Human Amniotic Membrane in the Treatment of Dystrophic Epidermolysis Bullosa Patients
|
N/A | |
Completed |
NCT01033552 -
Biochemical Correction of Severe EB by Allo HSCT and "Off-the-shelf" MSCs
|
Phase 1/Phase 2 | |
Completed |
NCT04227106 -
Phase 3, Open-label Clinical Trial of EB-101 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)
|
Phase 3 |